Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA

Introduction Based on data from the DESTINY-Breast03 trial, we performed a cost-effectiveness analysis of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had been previously treated with trastuzumab and a taxane from the US payer perspective. Methods We conducted a Markov model to assess the cost-effectiveness of T-DXd versus trastuzumab emtansine (T-DM1). The simulation time horizon for this model was the lifetime of patients. Transition probabilities were based on data from the DESTINY-Breast03 trial. Health utility data were derived from published studies. Outcome measures were costs (in 2022 US$), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses assessed the uncertainty of key model parameters and their joint impact on the base-case results. Results The base-case results found that T-DXd provided an improvement of 3.90 QALYs compared with T-DM1, and the ICER was $220,533 per QALY. The one-way sensitivity analysis demonstrated that the utility value of progression-free survival, hazard ratios of T-Dxd versus T-DM1, and cost of T-Dxd contributed substantial uncertainty to the model. Probabilistic sensitivity analysis predicted T-DXd being cost-effective compared to T-DM1 was 0, 1, 16, and 46% at willingness-to-pay of $50,000, $100,000, $150,000, and 200,000 per QALY, respectively. Conclusion T-DXd was unlikely to offer a reasonable value for the money spent compared to T-DM1 in a US payer setting..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:39

Enthalten in:

Advances in therapy - 39(2022), 10 vom: 09. Aug., Seite 4583-4593

Sprache:

Englisch

Beteiligte Personen:

Wang, Jingyan [VerfasserIn]
Yi, Yinzhi [VerfasserIn]
Wan, Xiaomin [VerfasserIn]
Zeng, Xiaohui [VerfasserIn]
Peng, Ye [VerfasserIn]
Tan, Chongqing [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Breast cancer
Cost-effectiveness
Markov model
Trastuzumab deruxtecan
Trastuzumab emtansine

Anmerkungen:

© The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s12325-022-02273-4

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC213198880X

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?